Ramucirumab as a second line therapy for advanced HCC : a significant achievement or a wasted opportunity for personalised therapy?
The second line treatment of hepatocellular carcinoma (HCC) has recently become an exciting area of interest since new emerging options have demonstrated survival benefits versus placebo. Unfortunately, predictive biomarkers are unavailable for these treatments. Ramucirumab, a monoclonal antibody against VEGFR-2, has demonstrated overall survival superiority against placebo as a second line therapy for patients with AFP > 400 ng/ml in the recent REACH-2 trial. This review will provide the current updated knowledge regarding the HCC cancerogenesis and angiogenic VEGF/VEGFR-2 pathways and the clinical development of ramucirumab in advanced HCC. This study will also critically assess the gaps in a previous negative phase III trial that tested other potentially useful treatments and suggest ways to modernise clinical trials and personalise therapy for advanced HCC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Investigational new drugs - 37(2019), 6 vom: 30. Dez., Seite 1274-1288 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Roviello, Giandomenico [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alphafetoprotein |
|---|
| Anmerkungen: |
Date Completed 24.04.2020 Date Revised 13.12.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s10637-019-00760-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM295021853 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM295021853 | ||
| 003 | DE-627 | ||
| 005 | 20231227130002.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10637-019-00760-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1224.xml |
| 035 | |a (DE-627)NLM295021853 | ||
| 035 | |a (NLM)30879152 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Roviello, Giandomenico |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Ramucirumab as a second line therapy for advanced HCC |b a significant achievement or a wasted opportunity for personalised therapy? |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.04.2020 | ||
| 500 | |a Date Revised 13.12.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The second line treatment of hepatocellular carcinoma (HCC) has recently become an exciting area of interest since new emerging options have demonstrated survival benefits versus placebo. Unfortunately, predictive biomarkers are unavailable for these treatments. Ramucirumab, a monoclonal antibody against VEGFR-2, has demonstrated overall survival superiority against placebo as a second line therapy for patients with AFP > 400 ng/ml in the recent REACH-2 trial. This review will provide the current updated knowledge regarding the HCC cancerogenesis and angiogenic VEGF/VEGFR-2 pathways and the clinical development of ramucirumab in advanced HCC. This study will also critically assess the gaps in a previous negative phase III trial that tested other potentially useful treatments and suggest ways to modernise clinical trials and personalise therapy for advanced HCC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Alphafetoprotein | |
| 650 | 4 | |a HCC | |
| 650 | 4 | |a Ramucirumab | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Vascular Endothelial Growth Factor Receptor-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 700 | 1 | |a Sohbani, Navid |e verfasserin |4 aut | |
| 700 | 1 | |a Petrioli, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Rodriquenz, Maria Grazia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Investigational new drugs |d 1993 |g 37(2019), 6 vom: 30. Dez., Seite 1274-1288 |w (DE-627)NLM013000160 |x 1573-0646 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2019 |g number:6 |g day:30 |g month:12 |g pages:1274-1288 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s10637-019-00760-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2019 |e 6 |b 30 |c 12 |h 1274-1288 | ||